Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

NCT02424955 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT02424955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02424955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
Lead sponsor
Stanford University
Phase
Not applicable
Overall status
Completed
Start date
November 18, 2014
Completion date
June 30, 2022
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer, liver carcinoma, liver tumor